Treatment of non-alcoholic steatohepatitis.
Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but is not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, alpha-tocopherol, metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NASH. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow-up. A better understanding of the pathogenesis and natural history of NASH will help to identify the subset of patients at risk of progressing to advanced liver disease and, hence, those patients who should derive the most benefit from medical therapy.
Angulo
Paul
P
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA.
Lindor
Keith D
KD
D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy; D005234:Fatty Liver / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy; D009765:Obesity / Q000150:complications / Q000628:therapy; D012307:Risk Factors